Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04984707
Other study ID # KX0826-US-1001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 28, 2019
Est. completion date October 24, 2019

Study information

Verified date July 2021
Source Suzhou Kintor Pharmaceutical Inc,
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following Topical Single Ascending Dose Administration


Description:

A total of 40 subjects will be evaluated with 32 subjects randomized to receive active drug and 8 subjects randomized to receive placebo in a double-blind fashion (ten subjects in each dose cohort with two subjects randomized to placebo for total of four dose cohorts).Subjects were to be assigned to 1 of the 4 dose levels, 3 mg. 12 mg, 48 mg and 96 mg of KX-826 or placebo to match the active product, administered as a topical application.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date October 24, 2019
Est. primary completion date April 11, 2019
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Are capable of giving informed consent and complying with study procedures; 2. Are males between the ages of 18 and 60 years, inclusive; 3. Have a clinical diagnosis of AGA; 4. Considered healthy by the PI, based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG and vital signs; 5. Have normal renal and hepatic function as determined by the screening laboratory results; 6. Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6 months before screening; 7. Body mass index (BMI) of 19.0 to 35.0 kg/m2 inclusive and body weight not less than 50 kg; 8. Willing and able to adhere to study restrictions and to be confined at the clinical research center. Exclusion Criteria: 1. Clinically significant history of gastrointestinal (GI), cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity; 2. Any visible skin disease, damage or condition at the application site which, in the opinion of the investigator, could compromise subject safety and/or interfere with the evaluation of the test site reaction; 3. Subject has any dermatological disorders of the scalp; 4. Subject has a history of hair transplants, hair weaves; 5. Subject has hypersensitivity to previously prescribed minoxidil or finasteride; 6. Known or suspected malignancy; 7. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBs Ag), or hepatitis C (HCV) antibody; 8. A hospital admission or major surgery within 30 days prior to screening; 9. Participation in any other investigational drug trial within 30 days prior to screening; 10. A history of prescription drug abuse, or illicit drug use within 6 months prior to screening; 11. A history of alcohol abuse according to medical history within 6 months prior to screening; 12. A positive screen for alcohol or drugs of abuse; 13. Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products) or acute loss of blood during the 90 days prior to screening; 14. Use of prescription or over the counter (OTC) medications, and herbal (including St John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use of acetaminophen at < 3g/day was permitted until 24 hours prior to dosing); 15. An unwillingness of male participants to use appropriate contraceptive measures if engaging in sexual intercourse with a female partner of childbearing potential. Appropriate measures include use of a condom and spermicide and, for female partners, use of an intrauterine device (IUD), diaphragm with spermicide, oral contraceptives, injectable progesterone, progesterone subdermal implants, or a tubal ligation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
KX0826
AR antagonist
Other:
Placebo
Placebo of KX-826

Locations

Country Name City State
United States inVentiv Health Clinical Research Services LLC Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
Suzhou Kintor Pharmaceutical Inc,

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of treatment-emergent adverse events (TEAE) by skin irritation assessments Skin irritation assessments will be performed during the treatment period. The dermal response score will be based on a visual irritation scale (0-7) that rates the degree of erythema, edema and other signs of cutaneous irritation. 3 days
Primary Incidence of treatment-emergent adverse events (TEAE) by vital signs measurements vital signs (including blood pressure, pulse rate, respiratory rate and oral temperatures) 3 days
Primary Incidence of treatment-emergent adverse events (TEAE) by ECG assessment 12-lead ECG 3 days
Primary Incidence of treatment-emergent adverse events (TEAE) by clinical lab tests hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count, with differential), blood chemistry (BUN, creatinine, total bilirubin, alkaline phosphatase, AST, ALT, GGT, LDH, glucose, albumin, total protein, bicarbonate, phosphate, sodium, potassium, chloride, calcium, total cholesterol, uric acid) and urinalysis (pH, specific gravity, protein, glucose, ketones, bilirubin, blood, nitrites, leukocytes, urobilinogen, microscopic urine analysis on abnormal findings) 3 days
Primary Incidence of study drug related TEAEs incidence of study drug related TEAEs (possibly, probably or definitely) 3 days
Secondary AUC from time 0 and extrapolated to infinite time, total exposure(AUCinf) Pharmacokinetics 48 hours
Secondary AUC from time 0 to the last non-zero concentration(AUClast) Pharmacokinetics 48 hours
Secondary Maximum observed concentration (Cmax) Pharmacokinetics 48 hours
Secondary Time at which Cmax was first observed(Tmax) Pharmacokinetics 48 hours
Secondary half life(T½) Pharmacokinetics 48 hours
Secondary Apparent total systemic clearance, calculated as Dose/AUCinf(Cl/F) Pharmacokinetics 48 hours
Secondary Apparent volume of distribution(Vd/F) Pharmacokinetics 48 hours
Secondary elimination rate constant(Kel) Pharmacokinetics 48 hours
See also
  Status Clinical Trial Phase
Completed NCT02591355 - Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment N/A
Withdrawn NCT03852992 - Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Phase 2
Recruiting NCT06239207 - Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia Phase 2
Completed NCT04945226 - A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 Phase 1/Phase 2
Completed NCT01437163 - Treatment of Androgenetic Alopecia in Males and Females N/A
Completed NCT01548066 - The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss Phase 2
Completed NCT01226459 - Clinical Trial in Females for Female Pattern Hair Loss Phase 3
Recruiting NCT06118866 - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia Phase 2
Completed NCT06149221 - Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss N/A
Withdrawn NCT04882969 - Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia N/A
Completed NCT01231607 - Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Phase 3
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT02729415 - Point-of-Care Adipose-derived Cells for Hair Growth N/A
Completed NCT02279823 - A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Phase 2
Not yet recruiting NCT01227031 - Pharmacogenomic Study of Androgenetic Alopecia N/A
Completed NCT00981461 - Treatment of Androgenetic Alopecia in Females, 9 Beam N/A
Completed NCT01451021 - A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Phase 2
Completed NCT00151515 - A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Phase 3
Completed NCT03694067 - Androgenetic Alopecia and the JAK-STAT Pathway
Completed NCT03689452 - The Effect of Platelet Rich Plasma on Non-scarring Alopecia N/A